Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to $1.1 billion.

  • Agilon Health's Other Accumulated Expenses fell 1102.47% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 1102.47%. This contributed to the annual value of $931.7 million for FY2024, which is 2628.9% up from last year.
  • As of Q3 2025, Agilon Health's Other Accumulated Expenses stood at $1.1 billion, which was down 1102.47% from $1.0 billion recorded in Q2 2025.
  • Agilon Health's Other Accumulated Expenses' 5-year high stood at $1.3 billion during Q1 2024, with a 5-year trough of $239.0 million in Q4 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $745.6 million (2023), whereas its average is $743.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 14525.56% in 2023, then tumbled by 1212.39% in 2025.
  • Quarter analysis of 5 years shows Agilon Health's Other Accumulated Expenses stood at $239.0 million in 2021, then grew by 25.85% to $300.8 million in 2022, then skyrocketed by 145.26% to $737.7 million in 2023, then rose by 26.29% to $931.7 million in 2024, then rose by 13.71% to $1.1 billion in 2025.
  • Its Other Accumulated Expenses stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.